CU6ASXClarity Pharmaceuticals Ltd

CU6 price activity

Last Price

Change (24hr)

AUD (%)

Volume

Volume (4w avg)

Previous Close

N/A

Last Trade

CU6 price performance

-4,25%

11,21%

-26,63%

YTD

-29,94%

CU6 price fundamentals

N/A

Shares Issued

N/A

Earnings Per Share (EPS)

N/A

Dividends Per Share (DPS)

N/A

P/E Ratio

Price market cap

Market cap

N/A

AU-ASX rank

N/A

Sector Rank

N/A

CU6 details

View company profile

View company website

View AU-ASX Official Page

Dividendos de CU6

Ver mais

quote.marketSignals

Mais formas de descobrir

Ver notícias de Australia Descubra sinais de ASX Ver todas as ações de ASX Ver todos os ETFs de ASX

Clarity Pharmaceuticals Ltd (AU-ASX: CU6)

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.

Price: A$2.48

Sector: Healthcare — Biotechnology